Company / Inventory
ALNYLAM PHARMACEUTICALS, INC. Inventory History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Inventory
$82.7M
FY2025
5-year range
$78.5M / $129.0M
FY2021-FY2025
Trend
+5.4%
vs FY2024
Sector context
#46 of 105
Health Care
What the data says
At $83M, ALNYLAM PHARMACEUTICALS, INC.'s inventory ranks #46 of 105 in the Health Care sector. Inventory returned to growth in FY2025 after 2 years of decline, reaching $83M.
Based on SEC 10-K filings.
$83M in FY2025 with a 5-year CAGR of +1.9%.
Declined from $89M to $83M over the past 2 years.
Health Care sector context is included.
Inventory over time
Growth rates
- 3-Year CAGR
- -13.8%
- 5-Year CAGR
- +1.9%
- 10-Year CAGR
- -
Sector benchmark
#46 of 105 in Health CareTop 44% of 105This company $82.7M Sector average $885.3M
▼
-90.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +1.9%, indicating consistent growth.
- In FY2025, inventory increased 5.4% year-over-year.
- Ranks #46 out of 105 companies in the Health Care sector.
- Peak inventory was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | InventoryValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $82.7M | +5.4% |
| FY2024 | $78.5M | -11.9% |
| FY2023 | $89.1M | -30.9% |
| FY2022 | $129.0M | +49.3% |
| FY2021 | $86.4M | +14.8% |
| FY2020 | $75.2M | +33.5% |
| FY2019 | $56.3M | +134.1% |
| FY2018 | $24.1M | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026